Key Points
- Medifast director Daniel Chard sold 9,544 shares at an average price of $11.73, generating $111,951.12. The transaction, conducted under a pre-arranged Rule 10b5-1 plan, reduced his ownership by 6.81% to 130,609 shares.
- Medifast reported quarterly EPS of -$0.28, beating the consensus estimate of -$0.65, while revenue of $76.38 million exceeded expectations. However, the company continues to post negative margins and analysts expect a full-year loss.
- Institutional investors and hedge funds own 95.51% of Medifast. Analysts have a consensus “Reduce” rating and a $12.00 price target, compared with the stock’s reported opening price of $11.53.
Medifast Inc (NYSE:MED - Get Free Report) Director Daniel Chard sold 9,544 shares of the firm's stock in a transaction that occurred on Tuesday, September 29th. The shares were sold at an average price of $11.73, for a total value of $111,951.12. Following the completion of the sale, the director directly owned 130,609 shares of the company's stock, valued at approximately $1,532,043.57. The trade was a 6.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Medifast Trading Down 0.7%
MED stock opened at $11.53 on Thursday. The firm has a market capitalization of $128.85 million, a PE ratio of -4.95 and a beta of 0.71. Medifast Inc has a 1-year low of $9.22 and a 1-year high of $14.15. The business's 50 day simple moving average is $11.67 and its 200 day simple moving average is $11.34.
Medifast (NYSE:MED - Get Free Report) last announced its quarterly earnings results on Monday, August 3rd. The specialty retailer reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.65) by $0.37. Medifast had a negative return on equity of 6.69% and a negative net margin of 8.08%.The business had revenue of $76.38 million during the quarter, compared to the consensus estimate of $72.70 million. Medifast has set its FY 2026 guidance at -1.750--0.250 EPS and its Q3 2026 guidance at -0.650--0.150 EPS. As a group, sell-side analysts predict that Medifast Inc will post -1.04 EPS for the current fiscal year.
Hedge Funds Weigh In On Medifast
Several institutional investors and hedge funds have recently modified their holdings of the business. Engineers Gate Manager LP raised its stake in Medifast by 25.9% in the 2nd quarter. Engineers Gate Manager LP now owns 49,829 shares of the specialty retailer's stock worth $529,000 after purchasing an additional 10,249 shares in the last quarter. Squarepoint Ops LLC acquired a new position in shares of Medifast during the 2nd quarter worth approximately $214,000. Chico Wealth RIA acquired a new position in shares of Medifast during the 2nd quarter worth approximately $223,000. Ancora Advisors LLC bought a new position in shares of Medifast during the second quarter worth approximately $75,000. Finally, Empowered Funds LLC bought a new position in shares of Medifast during the second quarter worth approximately $701,000. 95.51% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
MED has been the topic of several research analyst reports. Weiss Ratings raised shares of Medifast from a "sell (e+)" rating to a "sell (d)" rating in a report on Monday, August 17th. Zacks Research lowered Medifast from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 11th. Two analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Medifast presently has an average rating of "Reduce" and a consensus price target of $12.00.
View Our Latest Stock Report on MED
About Medifast
(
Get Free Report)
Medifast, Inc (NYSE: MED) is a health and wellness company that provides weight-management and healthy-lifestyle products and programs. Its principal brand is OPTAVIA, which offers structured plans designed to support weight loss, nutrition, and long-term habit development.
The company's product portfolio includes meal-replacement shakes, bars, snacks, entrees, beverages, supplements, and other packaged “Fuelings.” Medifast also supports customers through independent OPTAVIA Coaches, who provide guidance, accountability, and lifestyle support through the company's direct-selling model.
Founded in 1980, Medifast serves customers primarily in the United States through its e-commerce and direct-to-consumer channels.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
